DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysisLinda M. Henricks, Jan H.M. Schellens, Geert-Jan Creemers et al.|The Lancet Oncology|2018Cited by 419
Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.Manon Huizing, Jos H. Beijnen, Anther Keung et al.|Journal of Clinical Oncology|1993Cited by 313
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapyMarkus Joerger, Jan H.M. Schellens, Alwin D. R. Huitema et al.|Cancer Chemotherapy and Pharmacology|2015Cited by 55